Astellas' Xtandi joins elite group offering "major benefit," according to IQWiG
This article was originally published in Scrip
Executive Summary
Astellas Pharma's metastatic prostate cancer drug Xtandi (enzalutamide) has won over Germany's hard to please health technology assessment institute, IQWiG, which said the drug hints at major benefit in some patients, and considerable benefit in others. In doing so, the drug joins a small elite group of products to have earned the institute's top grade.